Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain

Cosı́n-Sales, Juan; Ruiz, Raquel Campuzano; Palencia, José Luis Díaz; Cervantes, C. Escobar; Olmo, María Rosa Fernández; Gómez‐Doblas, Juan José; Mostaza, José María; Botet, Juan Pedro; Gil, Núria Plana; Valdivielso, Pedro

doi:10.1016/j.atherosclerosis.2023.04.013

Cited by 7 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reasons for not using life-saving lipid lowering therapies despite solid evidence of the benefits (e.g., statins) are complex and inadequately understood, regardless the fact that the safety of statins has been extensively demonstrated [31]. Besides that, insufficient intensification of lipid lowering therapy is in part due to physicians' misperception on preventive LDL-C control [32]. Thus, our analysis suggested that long-term cardiovascular outcomes were increased in the group of patients with an upward variability.…”

Section: Discussionmentioning

confidence: 99%

LDL Cholesterol Variability Impacts the Prognosis of Patients with Chronic Ischemic Heart Disease: A Real-World Italian Experience

Faggiano,

Ruscica,

Bettari

et al. 2023

JCM

View full text Add to dashboard Cite

Epidemiologic, genetic, and clinical intervention studies have indisputably shown that low-density lipoprotein cholesterol (LDL-C) is causal in the development of atherosclerotic cardiovascular disease (ASCVD). However, LDL-C variability could be related to increased ASCVD risk in patients already treated with statins. The aim of the present retrospective real-life study was to assess the prognostic impact of LDL-C variability on all-cause mortality and cardiovascular hospitalizations in patients with stable cardiovascular artery disease. A total of 3398 patients were enrolled and followed up for a median of 56 months. Considering LDL-C < 70 mg/dL as the therapeutical target, during follow-up, the percentage of patients who achieved this goal raised from 20.7% to 31.9%. In total, 1988 events were recorded, of which 428 were all-cause deaths and 1560 were cardiovascular hospitalizations. At the last medical examination, each increase in LDL-C levels of 20 mg/dL corresponded to a 6% raise in the risk of any event (HR 1.06; 95%CI, 1.03 to 1.09). In conclusion, our real-world study supports the hypothesis that a continuous and progressive downward trend in LDL-C levels is needed to achieve and maintain a cardiovascular benefit, at least in secondary prevention.

show abstract

Section: Discussionmentioning

confidence: 99%